'Authorized Biosimilars' Cannot Use 351(k) Pathway

FDA Concludes Reference Product Must Be Another Biological Product

 
• By Sue Sutter
  
Calendar_23_March
US FDA is finalizing preparations for the regulatory transition that will take place on 23 March • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products